HBIO Stock Harvard Bioscience (HBIO, $0.46) Stochastic Oscillator left the oversold zone on October 02, 2025

GET DAILY SIGNALS

Get AI intraday signals

HBIO - Harvard Bioscience

Stochastic signal

View

Odds of UP Trend

Price: $0.4593

Daily change: +$0.0115 (+2.57%)

Daily volume: 431K

Industry: Pharmaceuticals: Other

HBIO in +4.74% Uptrend, advancing for three consecutive days on October 02, 2025

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where HBIO advanced for three days, in of 238 cases, the price rose further within the following month. The odds of a continued upward trend are .

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 63 cases where HBIO's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for HBIO just turned positive on October 02, 2025. Looking at past instances where HBIO's MACD turned positive, the stock continued to rise in of 52 cases over the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 30, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on HBIO as a result. In of 102 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

HBIO moved below its 50-day moving average on September 19, 2025 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for HBIO crossed bearishly below the 50-day moving average on September 11, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 11 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where HBIO declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for HBIO entered a downward trend on September 24, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. HBIO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.271) is normal, around the industry mean (10.969). P/E Ratio (0.000) is within average values for comparable stocks, (54.450). HBIO's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.741). HBIO has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.016). P/S Ratio (0.222) is also within normal values, averaging (14.774).

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HBIO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock worse than average.